Other mechanisms on which Metformin play an action are: mammalian target of rapamycin (mTOR, crucial to tumor cell metabolism), adenosine mono-phosphate-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase (mGPDH), and the nuclear factor kB (NF-kB) (Kushchayeva et al., 2014
This mechanism may be attributed to the interference with copper ion transport leading to increased ROS levels, mitochondrial dysfunction and reduced ATP production, ultimately inhibiting Cu/Zn SOD1 activity (136)
Eli Lilly's May 21, 2026 announcement reported mean body-weight reduction of 19.0% on 4 mg, 25.9% on 9 mg, and 28.3% on 12 mg, compared with 2.2% on placebo [1][2]
Diamond F, Eichler D, Mayes D, Jorgensen V, Duckett G, Hu C, Cuthbertson D, Root A
From current evidence, unrecognized MIS-A has a high mortality rate